HighTower Advisors LLC Sells 36,255 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

HighTower Advisors LLC trimmed its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 756,823 shares of the biopharmaceutical company’s stock after selling 36,255 shares during the period. HighTower Advisors LLC owned about 0.36% of Sangamo Therapeutics worth $772,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in SGMO. SBI Securities Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter worth about $28,000. XTX Topco Ltd increased its holdings in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares during the last quarter. State Street Corp lifted its holdings in shares of Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 145,400 shares in the last quarter. Finally, Golden State Equity Partners boosted its position in shares of Sangamo Therapeutics by 2,592.3% during the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 313,587 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.17.

Sangamo Therapeutics Stock Down 4.4 %

SGMO opened at $0.82 on Friday. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18. The company’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $1.40. The stock has a market cap of $184.26 million, a price-to-earnings ratio of -1.09 and a beta of 1.49.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.70 million. As a group, sell-side analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.